Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study
Authors' conclusion
Tirzepatide demonstrated clinically meaningful HbA1c reductions with favourable safety profiles in Japanese patients. The effectiveness was consistent across diverse subgroups, supporting its integration into diabetes management in Japan.
Study context
- Population
- Japanese patients with T2D initiating tirzepatide at three outpatient clinics, July 2023–August 2024; mean baseline HbA1c 7.7%, mean BMI 29.1 kg/m²; 82.3% prior antidiabetic therapy, incl. insulin 30.0%
- Participants
- 203 patients
- Outcome
- HbA1c change
- Follow-up
- 52 weeks
Methodological detailsmulti-site, Subgroup analyses on 22 predefined patient characteristics
- Multi-site
- Subgroup analyses on 22 predefined patient characteristics
Main finding
As reported in the abstract
Overall mean HbA1c reduction
−0.91%
95% CI −1.08 to −0.74p < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Incretin-naive | GLP-1 RA switchers | P value |
|---|---|---|---|
| HbA1c reduction by prior incretin use (subgroup)Greater reductions in incretin-naive | −1.19% | −0.65% | P = 0.005 |
Achieved HbA1c <7.0%
- Patients achieving HbA1c <7.0%
- 61.2%
Weight change
- Mean weight loss
- −3.4 kg
Treatment persistence
- Treatment persistence rate
- 92.6%
Effectiveness across subgroups
- Effectiveness consistent across diverse subgroups
Safety
- Gastrointestinal adverse events
- 6.4%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study. Diabetes Obes Metab. Published 12 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →